Comparative Pharmacology
Head-to-head clinical analysis: DIUTENSEN R versus TIMOLIDE 10 25.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DIUTENSEN R versus TIMOLIDE 10 25.
DIUTENSEN-R vs TIMOLIDE 10-25
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
DIUTENSEN-R is a combination of reserpine and chlorothiazide. Reserpine depletes catecholamines from peripheral sympathetic nerve endings by inhibiting vesicular monoamine transporter (VMAT), leading to reduced sympathetic tone. Chlorothiazide is a thiazide diuretic that inhibits sodium reabsorption in the distal convoluted tubule, promoting natriuresis and reducing plasma volume.
Timolol is a non-selective beta-adrenergic receptor antagonist that blocks beta-1 and beta-2 receptors, reducing heart rate, myocardial contractility, and blood pressure. Hydrochlorothiazide is a thiazide diuretic that inhibits the sodium-chloride symporter in the distal convoluted tubule, increasing excretion of sodium and water, reducing plasma volume and blood pressure.
One tablet orally once daily. Each tablet contains 2.5 mg reserpine and 25 mg chlorthalidone.
One tablet (timolol 10 mg / hydrochlorothiazide 25 mg) orally once daily. May be increased to two tablets once daily if needed.
None Documented
None Documented
Terminal half-life: cryptenamine 9-10 h, methylothiazide 18-24 h, reserpine 50-100 h (prolonged due to enterohepatic recirculation and tissue binding; accumulation occurs with daily dosing)
The terminal elimination half-life of timolol is approximately 4 hours in patients with normal renal function, but may be prolonged to 12-20 hours in patients with renal impairment or hepatic dysfunction. The half-life of hydrochlorothiazide is 6-15 hours.
Renal: 59% (cryptenamine), 50% (methylothiazide), 7% (reserpine); Biliary/fecal: 21% (cryptenamine), 48% (methylothiazide), 90% (reserpine)
Timolol is primarily eliminated by renal excretion of unchanged drug and metabolites. Approximately 20% of a dose is excreted unchanged in urine, with the remainder as metabolites (mostly inactive). Fecal elimination accounts for less than 5%.
Category C
Category C
Antihypertensive Combination
Antihypertensive Combination